

Floromox-XG

Moxifloxacin (enriched with Xanthan gum)

Composition:

Floromox-XG Ophthalmic Solution: Each ml contains Moxifloxacin Hydrochloride BP equivalent to Moxifloxacin 5 mg (enriched with Xanthan Gum BP 0.4%).

Pharmacology:

Moxifloxacin shows antibacterial activity by inhibiting the bacterial enzyme topoisomerase-II (DNA gyrase) and topoisomerase-IV.

Indication:

Floromox-XG is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of following organisms: Aerobic Gram-positive microorganisms: *Corynebacterium* species, *Micrococcus luteus*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus warneri*, *Streptococcus pneumoniae*, *Streptococcus viridans* group. Aerobic Gram-negative microorganisms: *Acinetobacter iwoffii*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*.

Dose & administration:

One drop in the affected eye's twice daily for 7 days.

Contraindication:

No information available.

Warning and Precaution:

Prolonged use may result in overgrowth of non-susceptible organisms, including fungi like with other anti-infectives.

Side Effect:

The most frequently reported ocular side effects are ocular discomfort, irritation etc. may occur.

Use in Pregnancy and Lactation:

Moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus as there are no adequate and well-documented studies in pregnant women.

Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when Moxifloxacin is administered to a lactating mother.

Use in Children & adolescents: The safety and effectiveness of Moxifloxacin in infants below four months of age was not proven. However, several clinical studies show that the drug may be used safely in children even younger than one month of age.

Geriatric Use:

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

Overdose:

No information available.

Drug Interaction:

Drug-drug interaction studies have not been conducted with Moxifloxacin Hydrochloride. In vitro studies indicate that Moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19 or CYP1A2 indicating that Moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isoenzymes.

Storage:

Store below 30° C at cool and dry place, protect from light. Keep out of reach of children.

Packing:

Floromox-XG Ophthalmic Solution: Each plastic dropper bottle contains 5 Sterile & Pyrogen free Ophthalmic Solution.



Manufactured by

The **IBN SINA** Pharmaceutical Industry Ltd.
Shafipur, Kaliakoir, Gazipur, Bangladesh